GlassScriptPhysician profile
Reda Issa
NPI 1255759981
$5,491.60
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,361 · 2020: $444 · 2021: $1,571 · 2022: $115.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,758.51 | 2019 | |
| Alimera Sciences, INC. | $1,369.30 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $704.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $657.12 | 2019-2021 | |
| Eyepoint US, INC. | $251.54 | 2020-2022 | |
| Allergan, INC. | $239.43 | 2019-2021 | |
| Dutch Ophthalmic, USA | $171.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $132.87 | 2019-2020 | |
| Genentech, INC. | $96.61 | 2019 | |
| Genentech USA, INC. | $38.55 | 2022 | |
| Mallinckrodt Enterprises LLC | $27.89 | 2019 | |
| Spark Therapeutics, INC. | $22.77 | 2022 | |
| Abbvie INC. | $20.73 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reda Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.